In a recent Stansberry Research presentation, Dr. David Eifrig teased three “Health Care Singularity” stocks that he says have the potential for 1,000% gains.
In short, it was part of a pitch for a new service he’s launched called Prosperity Investor, which costs $2,000 to join. And Eifrig reveals his stock picks in a report called “The No. 1 Opportunity of My Life: 3 Chances at 1,000%-Plus Gains in the Health Care Singularity,” which subscribers of the service get access to.
But I looked into Dr. Eifrig’s clues to see what I could find.
And I think I know what all three of his picks are, based on my research of the clues he shared in the presentation. So with that said, let’s get started.
What Is Dr. David Eifrig Predicting?
Dr. David Eifrig’s latest presentation centers around the health care sector and an event he calls the “Health Care Singularity,” which is supposedly a moment when data and artificial intelligence (AI) “empower treatments and cures unlike anything we’ve ever seen.”
“… an event I call the ‘Health Care Singularity.’
“A moment when data and artificial intelligence empower treatments and cures unlike anything we’ve ever seen – and they’re available to us almost instantly.
“This change could be bigger than electric cars… new forms of energy… or 21st century space exploration.”Source: https://orders.stansberryresearch.com/?cid=MKT649547&eid=MKT652546&assetId=AST250247&page=2
Eifrig described this so-called “Health Care Singularity” as the “digitization of everything in health” combined with “the computation tools to harness it.” And in the presentation, he made the following predictions about the impact this tech could have in five years:
“In five years, I can all but guarantee that the ideas I’ve talked about today will be obvious to everyone.
“I predict that the life sciences sector will have boomed to many times its current size…
“AI-driven care and computational drug development will be commonplace…
“Treatments will be fully personalized, built on a real-time stream of personal biomarkers a hundred times its current size…
“And lifesaving developments will translate from academic discovery to clinical practice virtually instantaneously.”
As for what he’s recommending, Eifrig suggested in the presentation that despite health care stocks being beaten down, the Health Care Singularity could provide investors with a “once-in-a-lifetime opportunity” to do two things.
First, he said that getting into certain “low-risk stocks” could “compound your wealth by 20% per year” or more (for decades) as a “total transformation of health unfolds.”
And he teased seven “forever stocks” he’s bullish on, which he reveals in a report called “7 ‘Forever’ Health Stocks to Potentially Double the Market, Every Year.”
Unfortunately, though, Eifrig didn’t reveal anything tangible about those seven companies, so I don’t know what those picks are.
However, aside from the above “forever stocks,” Eifrig said that the second “once-in-a-lifetime opportunity” is to get in cheaply and early on a “handful of innovators with 1,000%-plus upside potential in the Health Care Singularity.”
And he did share some tangible clues about these three picks.
So let’s take a look at these now.
Eifrig’s 3 “Health Care Singularity” Picks Revealed
David Eifrig reveals his three “Health Care Singularity” picks in a report called “The No. 1 Opportunity of My Life: 3 Chances at 1,000%-Plus Gains in the Health Care Singularity.”
And in this section, I’ll show you what I think they are.
Pick 1 (DermTech)
My research suggests that David Eifrig’s first “Health Care Singularity” pick is DermTech Inc (DMTK), as this company is the closest match with his clues. And to explain why I say that, here’s a summary of what Eifrig said about this company in the presentation:
“One of these companies created a simple, at-home test for an extremely deadly and common type of cancer.
“It affects more people than all other cancers combined.
“This technology is cheaper than existing detection methods and non-invasive. It can save millions of lives from early detection… and billions of dollars in in-person medical costs.
“It’s already approved by the FDA… covered by Medicare… and has some of the largest insurers in the largest states.
“The stock is so cheap today that it could rise 15-fold just to get back to where it was before the recent market freak-out. That’s a once-in-a-lifetime buying opportunity.”
I’m not a health expert, so the first thing I did was research what the most common type of cancer is, which appears to be skin cancer.
Second, I Googled what companies have a non-invasive skin cancer detection technology that matches what Eifrig said, and my research led me to DermTech.
DermTech is a California-based company that has developed the DermTech Melanoma Test, which the company site says “gently and non-invasively detects the presence of genomic markers associated with melanoma.”
In short, the company has developed a Smart Sticker™ that can apparently collect skin cells from a suspicious skin spot and test for melanoma without using a scalpel.
As I said, I’m not a health expert, so I have no idea how effective this test is or how it works beyond what the site says, but the tech seems pretty interesting.
As for clues Eifrig shared about the stock, it was trading at around $5 a share in June and early this month (July 2022), which is around the time Eifrig’s presentation was made. And it was trading at around $79 at its peak in February last year. So this stock appears to match his “could rise 15-fold just to get back to where it was before” clue.
The only thing I’m not sure about is how Eifrig said the technology is “already approved by the FDA” because, according to the company website, The DermTech Melanoma Test is not reviewed or approved by the FDA.
However, it’s still possible that this clue is at least a ballpark match.
How so? Well, the homepage of the company website explains that its DermTech Melanoma Test consists of two laboratory tests, one of which is called the Pigmented Lesion Assay (PLA) test and another known as the “plus add-on test.”
“The DermTech Melanoma Test consists of two laboratory tests performed on a single tissue collection: (i) the Pigmented Lesion Assay (PLA) test, is covered by Medicare; and (ii) plus (using remaining genomic material, if available, after the PLA is performed), the plus add-on test does not yet have Medicare coverage. The PLA test may be ordered without the plus add-on.”Source: https://dermtech.com
How does this relate to Eifrig’s clue?
Because if you read the above paragraph from the company site, it states that DermTech’s PLA test can be ordered on its own (i.e., without the plus add-on). And according to this document about the company’s PLA test, the FDA does not require this test to go through a premarket FDA review. So this may help explain Eifrig’s “approved by the FDA” clue.
Also, the company states that its PLA test is covered by Medicare, while the second “plus add-on test” isn’t. And since the PLA test can be ordered on its own, that may help explain what Eifrig said about the tech being “covered by Medicare.”
Of course, it’s possible Eifrig is talking about a different company. And this is all based on my own research, so I recommend doing your own due diligence here. But based on everything I found, my guess is that Eifrig’s first pick is DermTech.
Pick 2 (Butterfly Network)
Uncovering Eifrig’s second pick was pretty easy because what he said about this company reminded me of an Alex Green pitch about a handheld ultrasound device, which turned out to be a pitch for Butterfly Network (BFLY).
And as I looked into the clues, this appears to be Eifrig’s second pick.
To show you why I say that, here are Eifrig’s clues:
“Another is harnessing the power of medical AI, which I’ve told you so much about today.
“It’s handheld device plugs into any doctor’s smartphone, replacing machines that cost 10 times as much – without the AI!
“And making this screening available at the point of care – in doctor’s offices and even in the field, where before patients had to spend critical hours waiting for a specialist at the hospital.
“The founder is a trailblazer with three hugely successful companies already under his belt. He won a presidential award for his contributions to genome mapping. This latest venture is backed by Bill Gates, among others.
“Revenue was up 35% last year… and this AI-driven health company is just getting started.”
Now here’s an overview of why I think Butterfly Network is a match:
- Butterfly Network is a Connecticut-based company that, according to its website, has created the world’s first handheld whole-body imager. In short, the company’s device uses artificial intelligence, and not only is it smaller than traditional medical imaging machines, but it’s relatively cost-effective.
- The company’s founder, Jonathan Marc Rothberg, was awarded the National Medal of Technology and Innovation by former President Barack Obama in 2016, which was related to his work with DNA sequencing technologies.
- Lastly, Rothberg has founded numerous companies, and according to The Motley Fool, his latest venture, Butterfly Network, is backed by the Bill & Melinda Gates Foundation.
So to sum it up, I believe that Butterfly Network is Dr. David Eifrig’s second pick.
Pick 3 (Immatics NV)
Eifrig didn’t say much about his third “Health Care Singularity” pick, but what he did say has led me to think his pick could be Immatics NV (IMTX).
Here are Eifrig’s clues about this pick:
“The last company is a pure biotech play – with a chance at the astronomical gains you can see when a groundbreaking drug wins approval.
“Its technology was all the buzz at the latest American Society of Clinical Oncology meeting – the most prestigious cancer conference in the world.
“And they just penned a more than $4 billion partnership with pharma giant Bristol Myers Squibb.”
So we’re basically looking for a biotech company with a technology that was “all the buzz” at the latest American Society of Clinical Oncology (ASCO) meeting, and that has a $4 billion-plus partnership with Bristol Myers Squibb.
The most telling clue was the last one, which matches Immatics.
According to a June 2022 fiercebiotech.com article, Bristol Myers Squibb and Immatics are working on multiple collaborations to the tune of $4.2 billion.
As for the clue about the ASCO meeting, this one is hard to verify without understanding the ins and outs of the technology Immatics is working on, which I don’t.
But according to the company website, it is “committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.”
And while I don’t know if this company’s tech was “all the buzz” at the ASCO 2022 meeting, T cells appear to have been discussed at the ASCO meeting.
So, Eifrig’s third pick MIGHT be Immatics, but given the lack of clues, and nature of what this company does, I am not as confident about this guess as the last two.
Nevertheless, if you want to know what all three of Dr. Eifrig’s picks are, and get all the details about his recommendation, the best thing to do would be to check out his service, Prosperity Investor. Because as a subscriber, you get the reports I mentioned earlier, which come with a Prosperity Investor subscription.
Recommended: Go here to see my #1 rated stock advisory of 2022
What Is Prosperity Investor?
Prosperity Investor is a new Stansberry Research stock advisory service headed up by Dr. David Eifrig that’s focused on healthcare-related investments.
According to Eifrig, the service is aimed at showing subscribers how to thrive in the markets, retirement, and health.
“We named this research Prosperity Investor because I’m going to show you how to thrive in the markets… your retirement… your total wealth… and your health.”
Eifrig says that he and his team show subscribers how to profit from “every aspect of the future of health,” including pharmaceuticals, remote health, personalized medicine, and wearables.
“This research is where my team and I are going to show you how to profit from every aspect of the future of health.”
“Meaning not just how to beat sickness but to stay well.
“And how to use and profit from everything from breakthrough drugs… to remote health… to personalized medicine… to technologies like wearables.”
He also said that the service will share ideas related to cannabis and psychedelics companies and that Stansberry’s Thomas Carroll and John Engel will contribute to the information shared with subscribers of the Prosperity Investor service.
How much does it cost?
The presentation states that it costs $2,000 per year to join the Prosperity Investor service, and as part of the presentation, subscribers get a second year at no extra cost.
How does it work?
The way the service works is similar to most other services by the looks of it. As a subscriber, you get access to a new recommendation each month, updates on Eifrig’s picks, a model portfolio, and the reports I mentioned earlier (among others).
Is it worth it?
I am not a member of Prosperity Investor, so I don’t know how worthwhile it is (or isn’t). But Stansberry Research has been around for over 20 years, and David Eifrig appears to have recommended some decent health-related stocks in other services he runs, like Retirement Millionaire, his flagship service. So at the very least, I don’t think it’s a scam.
And it could be worthwhile if you’re interested in healthcare stocks.
That said, there’s no guarantee that any of Eifrig’s picks will make you money.
And according to the Stansberry Research website, it’s not possible to get a cash refund. So if you decide you don’t like Prosperity Investor, you can only get a refund credit to use on another Stansberry service. So that may be something to consider before joining.
David Eifrig’s latest investment presentation centers around the so-called “Health Care Singularity,” which he describes as the moment when data and artificial intelligence empower treatments and cures “unlike anything we’ve ever seen.”
And he teased three companies, which I think are DermTech, Butterfly Network, and Immatics, based on the clues Eifrig shared. I’m not as confident about my guess on the third company, but the first two seem like close matches.
Anyway, that’s my take.
What do you think?
Is the Health Care Singularity as big a deal as Eifrig claims? And do you think my guesses about his picks are on the money, or do you have a different idea?
Share your thoughts in the comments section below.
And thanks for reading!